Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis.
10.3349/ymj.2017.58.1.144
- Author:
Yoon Jee LEE
1
;
Jae Hee CHEON
;
Jae Hyun KIM
;
SunHo YOO
;
Hyun Jung LEE
;
Soo Jung PARK
;
Sung Pil HONG
;
Tae Il KIM
;
Won Ho KIM
Author Information
1. Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. geniushee@yuhs.ac
- Publication Type:Original Article
- Keywords:
Beclomethasone dipropionate;
ulcerative colitis;
clinical remission;
clinical response
- MeSH:
Administration, Oral;
Anti-Inflammatory Agents/*administration & dosage/adverse effects;
Beclomethasone/*administration & dosage/adverse effects;
Colitis, Ulcerative/drug therapy;
Drug-Related Side Effects and Adverse Reactions;
Female;
Humans;
Male;
Medical Records;
Remission Induction;
Republic of Korea;
Retrospective Studies;
Safety;
Treatment Outcome;
Young Adult
- From:Yonsei Medical Journal
2017;58(1):144-149
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Our aim was to evaluate the efficacy and safety of oral beclomethasone dipropionate (BDP) in Korean patients with ulcerative colitis (UC). MATERIALS AND METHODS: The medical records of patients with active UC who were treated with BDP were retrospectively reviewed. Partial Mayo Clinic score (pMS) was calculated to determine disease activity. After 4 weeks of therapy, clinical remission, clinical response, and response failure rates were evaluated. Clinical remission was defined as a post-treatment pMS of 0 or 1, clinical response as a decrease of two of three points in pMS and >30% from baseline, and response failure as a lack of clinical response. Also, we considered that clinical remission was included in clinical response. RESULTS: Between July 2013 and April 2015, 95 patients with UC received BDP therapy at our institution (median age, 44 years; range, 12–81 years). After 4 weeks of therapy, clinical remission and clinical response rates were 50.5% and 73.7%, respectively. Mean change of pMS before and after BDP therapy was 2.4. There was no significant side effect reported. In multivariate analysis, disease activity was the only factor associated with a favorable response. Clinical remission rate was significantly higher in the mild disease activity group (66.7%) than that in the moderate or severe disease activity group (41.9%) (p=0.024). CONCLUSION: BDP is efficacious in inducing a clinical response or remission in Korean patients with UC. Patients with mild UC were more likely to be in remission than those with moderate or severe UC after receiving BDP for 4 weeks. BDP exhibited a good safety profile.
